February 11, 2015
The aim of this study was to investigate if the intensity and adherence of PPI use among all patients with Barrett’s Esophagus in Denmark affected the risk of esophageal adenocarcinoma. There were 9883 patients with a new diagnosis of BE. The conclusions of the study revealed there were no cancer protective effects from PPI’s. In fact, high-adherence and long-term use of PPI were associated with a significantly increased risk of adenocarcinoma or high-grade dysplasia. The authors’ recommend continuous PPI therapy should be directed at symptom control and additional modalities considered as aid or replacement.
Here is the link to the article:
God bless you and to your good health!
Joyce Gibb MS, CRNP
Ask The Pharmacist Group, LLC